BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is a top healthcare stock with high upside potential, according to analysts. Cantor Fitzgerald’s Olivia Brayer maintained a Buy rating but lowered the price target from $90 to $80. J.P. Morgan’s Jessica Fye also gave a Buy rating with a target of $119 on October 9.

New data from 14 studies by BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) was presented at ASBMR. Results showed anatomical improvements in spinal morphology in children treated with VOXZOGO® (vosoritide), with continued efficacy post-puberty. BMO Capital’s Kostas Biliouris maintained a Buy rating with a $115 price target, highlighting growth prospects.

Analysts see potential in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) due to the expansion of Palynziq into the adolescent market. The company develops therapies for serious medical conditions and rare diseases, with a product pipeline that includes Valoctocogene roxaparvovec, Vosoritide, and BMN 307. While BMRN shows promise, other AI stocks may offer greater upside potential with less risk.

Read more at Yahoo Finance: Cantor Fitzgerald Reiterates a Buy Rating for BioMarin Pharmaceutical (BMRN)